Rizwan Romee, Associate Professor at Dana-Farber Cancer Institute, shared about a recent paper Mubin Tarannum et al. titled “CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer” published in Science.
Authors: Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara, Grace Birch, Yasmin Z. Abdulhamid, Isabel E. Kaplan, Oyku Ay, Andreia Maia, Owen Beaver, Rizwan Romee et al.
Rizwan Romee shared on X:
“Excited to share this paper from my lab led by outstanding scientist Dr. Mubin Tarannum romeelab CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer | Science Advances.
Our MSLN-CAR CIML NK cells demonstrated promising efficacy against various ovarian ca lines (even after exposed to highly immune suppressive ascitic fluid), PDX cells and in a xenograft model.
Memory-NK cells had several key gene expression changes (vs conventional NK cells and these may help prevent their immune suppression in the TME (including in ascitic fluid)
Rebecca Porter from our GYN-Onc group and also the DFCI Ovarian Ca SPORE from National Cancer Institute which partly funded this project. Planning a clinical trial in the near future.”
Katy Rezvani shared Rizwan Romee’s, Associate Professor at Dana-Farber Cancer Institute, post on X, adding:
“Congratulations Mubin and Rizwan Romee on this elegant paper. Very excited about the therapeutic potential of memory-like NK cells.”
Source: Katy Rezvani/X and Rizwan Romee/X
Katy Rezvani, holds roles including Professor of Medicine, Director of Translational Research, and Chief of the Section of Cellular Therapy at MD Anderson Cancer Center, . Previously, she directed stem cell transplant programs and research laboratories at Hammersmith Hospital, London. Dr. Rezvani’s research focuses on enhancing natural killer (NK) cell function against leukemia, utilizing genetic engineering techniques. Her work has led to funded Phase I/II trials in leukemia and lymphoma immunotherapy. .
